Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Laura Waters(Central and North West London NHS Foundation Trust), Luminita Schneider, Georg M. N. Behrens(Medizinische Hochschule Hannover), Mark Gompels, Els Caluwé(Ghent University Hospital), Christine Katlama(Université Paris Cité), Clotilde Allavena(Centre Hospitalier Universitaire de Nantes), Ana Gonzalez‐Cordón, David Boutoille(Inserm), Julie Fox(National Health Service), J. Connault, Christoph Stephan(Goethe University Frankfurt), Coca Necsoi(Centre Hospitalier Universitaire de Saint-Pierre), Thierry Le Tourneau, Adriana Pinto, Elisabeth André‐Garnier, Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Miresta Prévilon(Délégation Paris 7), Anton Pozniak, Stefano Rusconi(University of Milan), Jürgen K. Rockstroh(University of Bonn), Graeme Moyle(Chelsea and Westminster Hospital), Nadine Ktorza, Véronique Reliquet, Peré Domingo(Hospital de Sant Pau), Éric Florence(Instituut voor Tropische Geneeskunde), Linos Vandekerckhove(Ghent University Hospital), Stefan Eßer(Essen University Hospital), Mar Masiá(Universidad de Alcalá), Estebán Martínez(Instituto de Salud Carlos III), Maartje Van Frankenhuijsen, Lambert Assoumou(Inserm), Margaret Johnson(Duke University), François Raffi(Centre Hospitalier Universitaire de Nantes), Véronique Joly(ViiV Healthcare (United Kingdom)), Yazdan Yazdanpanah(Inserm), Roland Landman, José M. Gatell(Hospital Clínic de Barcelona), Hans‐Jürgen Stellbrink, Audrey Rodallec, Morane Cavellec, Samuel Ferret, Fabienne Caby, Giovanni Guaraldi(University of Modena and Reggio Emilia)
Clinical Infectious Diseases
October 18, 2022
Cited by 17


Related Papers